Coming in 2020
This innovative continuing professional development initiative represents one of the early efforts to advance oncology care, from the perspective of cardiotoxicity. This live peer-to-peer event will consist of didactic podium presentations, clinically-centric panel discussions, and audience participation.
Target audience of primary care physicians, physician extenders, oncologists, cardiologists, and medical trainees.
6.25 AMA PRA Category 1 Credit(s)™ (CME)
6.25 Continuing Nursing Education Credits available
6.25 Pharmacy CE contact hours CE Contact Hours
- To provide state-of-the art Best Practice Information regarding the continuum of Cardiac care for the oncology patient.
At the conclusion of this accredited and team-based initiative, the Learners will be able to:
- Define the risks of cancer treatment-related cardiac dysfunction for patients who have undergone therapy for cancer.
- Implement strategies for early detection, correction of cardiac risk factors and close and long-term cardiac monitoring in order to reduce the effects of cardiotoxicity for patients who are at risk of cancer treatment-related cardiac dysfunction, including heart failure, valvular dysfunction and autonomic dysfunction.
- Assess appropriate and effective treatment strategies and referral for patients who have long-term toxicity-related cardiac dysfunction, including heart failure, valvular dysfunction and autonomic dysfunction.